MedTrace Logo

Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Primary Hepatocellular Carcinoma (HCC)

NCT01308645 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2011-06-10

No results posted yet for this study

Summary

The purpose of this study is to determine efficacy of SB injection in Hepatocellular Carcinoma (HCC).

Conditions

Interventions

DRUG

SB injection

Infusion SB injection of 21.87 ml/m\^2, IV route, 24 times for 4 months

Sponsors & Collaborators

  • SBPharmaceutical IND, Co., LTD

    lead INDUSTRY

Principal Investigators

  • Lee Jin woo, Prof. · Inha University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2011-12-31
Completion
2012-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01308645 on ClinicalTrials.gov